Related Experiment Videos
[Management of postmenopausal osteoporosis]
Claude Ribot1, Florence Trémollières, Jean-Michel Pouillès
1Unité de ménopause et maladies osseuses métaboliques, hôpital Paule de Viguier, TSA 70034, 31059 Toulouse Cedex 9. ribot.c@chu-toulouse.fr
La Revue Du Praticien
|April 15, 2005
Summary
Effective postmenopausal osteoporosis management involves risk assessment using bone density and clinical factors. Early screening and tailored treatments, including anti-osteoclastic and anabolic drugs, improve fracture prevention strategies.
Area of Science:
- Endocrinology
- Gerontology
- Orthopedics
Context:
- Current postmenopausal osteoporosis management has advanced in screening high-risk individuals and developing effective fracture-reducing drugs.
- Assessing fracture risk requires integrating bone mineral density (BMD) with clinical risk factors.
- Biochemical markers of bone turnover can aid in refining risk evaluations.
Purpose:
- To review current strategies for managing postmenopausal osteoporosis.
- To highlight the importance of accurate fracture risk assessment.
- To discuss available and emerging therapeutic options.
Summary:
- Optimizing postmenopausal osteoporosis care involves comprehensive fracture risk assessment, combining BMD, clinical factors, and potentially bone turnover markers.
- Therapeutic choices range from hormone replacement therapy (with limited indications) to anti-osteoclastic drugs and novel anabolic compounds.
- A long-term prevention strategy should incorporate early screening for high-risk women and personalized treatment selection based on age and comorbidities.
Impact:
- Enables more precise identification of women requiring intervention for osteoporosis.
- Facilitates the selection of optimal treatments to reduce fracture incidence.
- Supports the development of personalized, long-term strategies for osteoporosis prevention and management.